Biomarkers in the Diagnosis of ADHD – Promising Directions

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The etiology and pathogenesis of attention-deficit/hyperactivity disorder (ADHD) are unclear and a more valid diagnosis would certainly be welcomed. Starting from the literature, we built an hypothetical pyramid representing a putative set of biomarkers where, at the top, variants in DAT1 and DRD4 genes are the best candidates for their associations to neuropsychological tasks, activation in specific brain areas, methylphenidate response and gene expression levels. Interesting data come from the noradrenergic system (norepinephrine transporter, norepinephrine, 3-methoxy-4-hydroxyphenylglycol, monoamine oxidase, neuropeptide Y) for their altered peripheral levels, their association with neuropsychological tasks, symptomatology, drugs effect and brain function. Other minor putative genetic biomarkers could be dopamine beta hydroxylase and catechol-O-methyltransferase. In the bottom, we placed endophenotype biomarkers. A more deep integration of “omics” sciences along with more accurate clinical profiles and new high-throughput computational methods will allow us to identify a better list of biomarkers useful for diagnosis and therapies.

Original languageEnglish
JournalCurrent Psychiatry Reports
Volume16
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Attention Deficit Disorder with Hyperactivity
Biomarkers
Norepinephrine Plasma Membrane Transport Proteins
Endophenotypes
Catechol O-Methyltransferase
Dopamine beta-Hydroxylase
Methylphenidate
Neuropeptide Y
Monoamine Oxidase
Brain
Norepinephrine
Gene Expression
Direction compound
Pharmaceutical Preparations
Genes
Therapeutics

Keywords

  • Attention-deficit/hyperactivity disorder
  • Biomarkers
  • CNS developmental network
  • COMT
  • DBH
  • Dopaminergic pathway
  • DRD4
  • EEG Theta/Beta ratio
  • Endophenotypes
  • Environmental risk factors
  • Executive functions
  • Metabolism enzymes
  • Noradrenergic pathway
  • Reaction time variability
  • SLC6A3
  • Vigilance/sustained attention
  • Working memory

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Biomarkers in the Diagnosis of ADHD – Promising Directions. / Faraone, Stephen V.; Bonvicini, Cristian; Scassellati, Catia.

In: Current Psychiatry Reports, Vol. 16, No. 11, 2014.

Research output: Contribution to journalArticle

@article{c9018986f1a5466fbaed4bf57ec23351,
title = "Biomarkers in the Diagnosis of ADHD – Promising Directions",
abstract = "The etiology and pathogenesis of attention-deficit/hyperactivity disorder (ADHD) are unclear and a more valid diagnosis would certainly be welcomed. Starting from the literature, we built an hypothetical pyramid representing a putative set of biomarkers where, at the top, variants in DAT1 and DRD4 genes are the best candidates for their associations to neuropsychological tasks, activation in specific brain areas, methylphenidate response and gene expression levels. Interesting data come from the noradrenergic system (norepinephrine transporter, norepinephrine, 3-methoxy-4-hydroxyphenylglycol, monoamine oxidase, neuropeptide Y) for their altered peripheral levels, their association with neuropsychological tasks, symptomatology, drugs effect and brain function. Other minor putative genetic biomarkers could be dopamine beta hydroxylase and catechol-O-methyltransferase. In the bottom, we placed endophenotype biomarkers. A more deep integration of “omics” sciences along with more accurate clinical profiles and new high-throughput computational methods will allow us to identify a better list of biomarkers useful for diagnosis and therapies.",
keywords = "Attention-deficit/hyperactivity disorder, Biomarkers, CNS developmental network, COMT, DBH, Dopaminergic pathway, DRD4, EEG Theta/Beta ratio, Endophenotypes, Environmental risk factors, Executive functions, Metabolism enzymes, Noradrenergic pathway, Reaction time variability, SLC6A3, Vigilance/sustained attention, Working memory",
author = "Faraone, {Stephen V.} and Cristian Bonvicini and Catia Scassellati",
year = "2014",
doi = "10.1007/s11920-014-0497-1",
language = "English",
volume = "16",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Biomarkers in the Diagnosis of ADHD – Promising Directions

AU - Faraone, Stephen V.

AU - Bonvicini, Cristian

AU - Scassellati, Catia

PY - 2014

Y1 - 2014

N2 - The etiology and pathogenesis of attention-deficit/hyperactivity disorder (ADHD) are unclear and a more valid diagnosis would certainly be welcomed. Starting from the literature, we built an hypothetical pyramid representing a putative set of biomarkers where, at the top, variants in DAT1 and DRD4 genes are the best candidates for their associations to neuropsychological tasks, activation in specific brain areas, methylphenidate response and gene expression levels. Interesting data come from the noradrenergic system (norepinephrine transporter, norepinephrine, 3-methoxy-4-hydroxyphenylglycol, monoamine oxidase, neuropeptide Y) for their altered peripheral levels, their association with neuropsychological tasks, symptomatology, drugs effect and brain function. Other minor putative genetic biomarkers could be dopamine beta hydroxylase and catechol-O-methyltransferase. In the bottom, we placed endophenotype biomarkers. A more deep integration of “omics” sciences along with more accurate clinical profiles and new high-throughput computational methods will allow us to identify a better list of biomarkers useful for diagnosis and therapies.

AB - The etiology and pathogenesis of attention-deficit/hyperactivity disorder (ADHD) are unclear and a more valid diagnosis would certainly be welcomed. Starting from the literature, we built an hypothetical pyramid representing a putative set of biomarkers where, at the top, variants in DAT1 and DRD4 genes are the best candidates for their associations to neuropsychological tasks, activation in specific brain areas, methylphenidate response and gene expression levels. Interesting data come from the noradrenergic system (norepinephrine transporter, norepinephrine, 3-methoxy-4-hydroxyphenylglycol, monoamine oxidase, neuropeptide Y) for their altered peripheral levels, their association with neuropsychological tasks, symptomatology, drugs effect and brain function. Other minor putative genetic biomarkers could be dopamine beta hydroxylase and catechol-O-methyltransferase. In the bottom, we placed endophenotype biomarkers. A more deep integration of “omics” sciences along with more accurate clinical profiles and new high-throughput computational methods will allow us to identify a better list of biomarkers useful for diagnosis and therapies.

KW - Attention-deficit/hyperactivity disorder

KW - Biomarkers

KW - CNS developmental network

KW - COMT

KW - DBH

KW - Dopaminergic pathway

KW - DRD4

KW - EEG Theta/Beta ratio

KW - Endophenotypes

KW - Environmental risk factors

KW - Executive functions

KW - Metabolism enzymes

KW - Noradrenergic pathway

KW - Reaction time variability

KW - SLC6A3

KW - Vigilance/sustained attention

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=84920896018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920896018&partnerID=8YFLogxK

U2 - 10.1007/s11920-014-0497-1

DO - 10.1007/s11920-014-0497-1

M3 - Article

C2 - 25298126

AN - SCOPUS:84920896018

VL - 16

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 11

ER -